Post-earnings recap
Reported
Wed, Apr 29, 2026
EPS actual
$-0.36
EPS est.
$-0.32
EPS surprise
-13.92%
1-day move
-0.83%
Teladoc Health's earnings report shows a smaller loss than expected on EPS, but the lack of revenue data leaves uncertainty. The stock reacted negatively, declining by 0.83%. Investors may be concerned about the absence of revenue figures and future guidance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.36 | $-0.39 | +13.92% |
| Revenue | — | $611M | — |
No transcript is on record for the earnings call, so the analysis is based solely on numerical results.
Teladoc Health Inc (TDOC) is a leader in the health care technology sector, providing virtual healthcare services. As telehealth continues to grow in popularity, especially post-pandemic, Teladoc's role in delivering accessible medical care is increasingly significant.
Last quarter
In Q4 2025, Teladoc reported an EPS of $-0.14, beating estimates by 27.46%. However, revenue details were not disclosed, leading to a modest stock increase of 2.42% the following day.
Management promises and guidance
EPS beat streak
1Q
EPS beat rate
50%
Avg EPS surprise
-2.59%
Avg 1-day reaction
-1.79%
Analysts are cautiously optimistic about Teladoc's upcoming earnings, with expectations for a narrower loss and stable revenue growth. However, the company's recent performance has been inconsistent, leading to mixed sentiments.
Bull case
If Teladoc can demonstrate significant revenue growth and a smaller loss than expected, it could signal a turnaround in its business model, attracting more investors.
Bear case
Conversely, if the company fails to meet revenue expectations or reports a wider loss, it could further erode investor confidence and lead to a decline in stock price.
Key metrics to watch
EPS
$-0.39Earnings per share (EPS) is a key indicator of profitability, and investors will be watching to see if Teladoc can narrow its losses this quarter.
Revenue
$611MRevenue growth is crucial for assessing the company's ability to attract and retain customers in a competitive market.
The print will turn on these.
Q1
Will Teladoc's revenue exceed the consensus estimate of $611M?
Revenue growth is critical for demonstrating the company's ability to attract and retain customers in a competitive market.
Q2
Can Teladoc narrow its EPS loss to better than the consensus of $-0.39?
A smaller loss could indicate improved operational efficiency and a potential turnaround in profitability.
—
Est. EPS
$1.52
Est. Rev
$3.6B
Impl. Move
±39.2%
Why consensus could be wrong
The consensus may underestimate Teladoc's potential for revenue growth due to its expanding service offerings and increased demand for telehealth.
Supporting evidence
Recent trends show a growing acceptance of telehealth services, which could drive higher revenue than anticipated.
The options market is pricing in a significant move, suggesting that investors expect a more substantial reaction than what consensus reflects.
Key risk
If Teladoc's revenue exceeds $626M, it would challenge the current bearish sentiment and indicate stronger market demand.
Pre-commit to what would confirm each case.
This quarter's performance is crucial for assessing Teladoc's recovery trajectory and its ability to compete in the growing telehealth market.
Bull confirmed if
Revenue growth exceeding $611M with EPS loss of less than $-0.39 would confirm the bull case.
Bear confirmed if
Revenue falling below $604M or an EPS loss greater than $-0.39 would confirm the bear case.
What the market is pricing for the move.
Implied Move
±17.31%
Historical Avg
±2.4%
The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.
Options are pricing ±17.3% while TDOC has averaged ±2.4% over the last 8 prints — setup is pricing rich.
30d HV
61.5%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$3,702.72
655 sh
1 insider
Net
$3,702.72
Net selling
Most Active Insiders· 1 open-market trade
$3,702.72
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
86.83%
of float
Insider
0.74%
of float
Holders
468
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
16,223,134 sh · $90.2M
8.93%
11.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Teladoc beats expectations, history suggests a potential stock increase of around 2.12%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
A miss on earnings could lead to a decline of approximately 2.23%, reflecting ongoing concerns about the company's profitability.
The lines on the call that would change the story.
Recent Transactions
Oct 2, 2026 · @ $5.65
655 sh
$3,702.72
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Vanguard Portfolio Management LLC
12,685,592 sh · $70.5M
6.98%
3.2%
Point72 Asset Management, L.P.
8,239,927 sh · $45.8M
4.54%
6.7%
Renaissance Technologies, LLC
8,072,842 sh · $44.9M
4.44%
-0.2%
Voss Capital, LP
8,046,679 sh · $44.7M
4.43%
91.6%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.